MGTX - MeiraGTx Holdings plc Stock Price, Fair Value and News

5.71USD+0.03 (+0.53%)Delayed

Market Summary

USD5.71+0.03

Delayed

0.53%

MGTX Stock Price

View Fullscreen

MGTX RSI Chart

MGTX Valuation

Market Cap

367.2M

Price/Earnings (Trailing)

-4.96

Price/Sales (Trailing)

26.2

EV/EBITDA

-4.36

Price/Free Cashflow

-3.11

MGTX Price/Sales (Trailing)

MGTX Profitability

EBT Margin

-599.46%

Return on Equity

-60.87%

Return on Assets

-23.96%

Free Cashflow Yield

-32.12%

MGTX Fundamentals

MGTX Revenue

Revenue (TTM)

14.0M

Rev. Growth (Yr)

-49.94%

Rev. Growth (Qtr)

-60.02%

MGTX Earnings

Earnings (TTM)

-74.1M

Earnings Growth (Yr)

32.68%

Earnings Growth (Qtr)

-201.12%

Breaking Down MGTX Revenue

Last 7 days

12.6%

Last 30 days

8.8%

Last 90 days

-5.8%

Trailing 12 Months

-25.4%

How does MGTX drawdown profile look like?

MGTX Financial Health

Current Ratio

3.14

MGTX Investor Care

Shares Dilution (1Y)

8.08%

Diluted EPS (TTM)

-1.18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	15.4M	15.0M	14.5M	14.0M
2022	38.7M	44.4M	42.3M	15.9M
2021	15.9M	18.6M	20.4M	37.7M
2020	16.7M	17.2M	18.7M	15.6M
2019	0	0	0	13.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of MeiraGTx Holdings plc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 05, 2024	forbes alexandria	gifted	-	-	-1,000	president & ceo
Mar 12, 2024	forbes alexandria	gifted	-	-	-2,000	president & ceo
Feb 29, 2024	giroux richard	gifted	-	-	-13,500	cfo & coo
Jan 14, 2024	zeldin robert k	sold (taxes)	-93,848	6.36	-14,756	chief medical officer
Jan 14, 2024	naylor stuart	sold (taxes)	-70,996	6.36	-11,163	chief dev. officer
Jan 14, 2024	forbes alexandria	sold (taxes)	-100,889	6.36	-15,863	president & ceo
Jan 14, 2024	forbes alexandria	acquired	-	-	30,000	president & ceo
Jan 14, 2024	zeldin robert k	acquired	-	-	37,500	chief medical officer
Jan 14, 2024	naylor stuart	acquired	-	-	23,750	chief dev. officer
Jan 14, 2024	giroux richard	sold (taxes)	-84,072	6.36	-13,219	cfo & coo

Which funds bought or sold MGTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-66.05	-385,537	160,205	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.9	-17,772	19,904	-%
May 16, 2024	Ancora Advisors LLC	unchanged	-	-523	3,338	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-70,741	-	-%
May 15, 2024	D. E. Shaw & Co., Inc.	added	88.03	160,735	417,555	-%
May 15, 2024	ZACKS INVESTMENT MANAGEMENT	new	-	92,319	92,319	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-71.04	-1,243,570	415,364	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	reduced	-46.83	-388,068	330,184	-%
May 15, 2024	683 Capital Management, LLC	unchanged	-	-2,375,000	15,175,000	1.11%
May 15, 2024	Laurion Capital Management LP	unchanged	-	-349,540	2,233,380	0.02%

Are Funds Buying or Selling MGTX?

Are funds buying MGTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MGTX

No. of Funds

Unveiling MeiraGTx Holdings plc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	perceptive advisors llc	18.0%	11,442,562	SC 13D/A
Feb 13, 2024	prosight management, lp	6.4%	4,050,714	SC 13G/A
Feb 07, 2024	adage capital partners gp, l.l.c.	8.32%	5,291,618	SC 13G/A
Nov 06, 2023	sanofi	7.4%	4,697,737	SC 13G
May 16, 2023	perceptive advisors llc	19.1%	11,406,563	SC 13D/A
May 15, 2023	prosight management, lp	6.9%	4,078,804	SC 13G
Feb 14, 2023	orbimed advisors llc	0%	0	SC 13G/A
Feb 09, 2023	adage capital partners gp, l.l.c.	6.41%	3,105,800	SC 13G/A
Nov 14, 2022	johnson & johnson	13.7%	6,641,064	SC 13G/A
Feb 11, 2022	orbimed advisors llc	8.1%	3,593,966	SC 13G/A

Recent SEC filings of MeiraGTx Holdings plc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
Apr 25, 2024	DEFA14A	DEFA14A
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	ARS	ARS
Apr 16, 2024	8-K/A	Current Report
Apr 08, 2024	4	Insider Trading
Mar 15, 2024	10-K	Annual Report
Mar 14, 2024	8-K	Current Report
Mar 14, 2024	4	Insider Trading

Peers (Alternatives to MeiraGTx Holdings plc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

MeiraGTx Holdings plc News

Latest updates

MeiraGTx Holdings plc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-60.0%	2,040,000	5,103,000	3,540,000	3,334,000	4,075,000	4,816,000	10,759,000	5,633,000	21,042,500	6,948,000	5,116,000	4,595,000	3,787,500	5,092,000	2,474,000	4,210,000	6,942,734	3,582,586	1,981,676	784,960
Operating Expenses	20.9%	45,794,000	37,865,000	32,325,000	35,094,000	35,767,000	27,624,000	34,517,000	34,367,000	28,733,000	29,500,000	25,599,000	26,627,000	17,006,500	13,522,000	27,699,000	19,889,000	12,386,070	14,489,256	23,208,925	21,475,704
S&GA Expenses	21.1%	12,124,000	10,009,000	12,388,000	12,772,000	14,002,000	10,762,000	10,518,000	11,268,000	15,551,000	7,887,000	10,409,000	9,918,000	12,007,500	8,896,000	11,497,000	11,806,000	14,872,841	9,874,810	13,437,171	8,499,475
R&D Expenses	20.9%	33,670,000	27,856,000	19,937,000	22,322,000	21,765,000	16,862,000	23,999,000	23,099,000	13,182,000	21,613,000	15,190,000	16,709,000	4,999,000	4,626,000	16,202,000	8,083,000	-2,486,771	4,614,446	9,771,754	12,976,229
EBITDA Margin	37.2%	-4.07	-6.48	-6.48	-6.56	-6.62	-0.88	-0.88	-1.01	-1.05	-1.97	-2.22	-	-	-	-	-	-	-	-	-
Interest Expenses	2.0%	3,449,000	3,381,000	3,355,000	3,060,000	2,895,000	1,892,000	82,000	77,000	119,000	59,000	51,000	59,000	36,000	35,000	34,000	34,000	20,301	9,283	9,454	9,574
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-338,670	-91,390	-
Earnings Before Taxes	-	-	-	-	-	-82,084,142	-	-	-	-	-	-	-	-	-6,431,727	-25,417,934	-	-5,050,991	-10,799,524	-20,913,802	-
EBT Margin	27.0%	-5.99	-8.21	-7.95	-7.70	-7.47	-1.13	-1.07	-1.23	-1.27	-2.33	-2.57	-	-	-	-	-	-	-	-	-
Net Income	145.6%	20,215,000	-44,297,000	-29,581,000	-30,364,000	-27,313,000	-37,284,000	-33,973,000	-31,045,000	-9,912,000	-25,945,000	-20,086,000	-23,618,000	-10,461,000	-6,432,000	-25,418,000	-15,681,000	-5,481,051	-10,460,854	-20,822,412	-17,981,918
Net Income Margin	34.0%	-5.99	-9.08	-8.32	-8.35	-8.14	-2.66	-2.27	-2.25	-2.11	-3.92	-3.26	-	-	-	-	-	-	-	-	-
Free Cashflow	37.2%	-17,577,000	-27,978,000	-33,979,000	-46,005,000	-24,759,000	-30,737,000	-41,807,000	-20,758,000	-5,541,000	-29,088,000	-26,836,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-5.4%	309	327	267	310	288	318	301	252	288	320	303	327	340	364	293	291	305	324	318	253	258
Current Assets	-6.5%	149	160	104	143	121	154	155	104	143	183	177	207	230	273	218	235	251	269	271	213	231
Cash Equivalents	-7.2%	120	130	63.00	93.00	69.00	116	115	72.00	114	138	144	173	199	210	179	195	211	227	253	204	227
Net PPE	-3.9%	111	116	112	114	113	109	94.00	91.00	84.00	76.00	64.00	55.00	47.00	44.00	35.00	28.00	25.00	24.00	17.00	16.00	16.00
Liabilities	-0.6%	188	189	175	187	198	200	179	110	126	135	115	121	119	125	114	118	120	133	123	124	113
Current Liabilities	-29.1%	48.00	67.00	64.00	72.00	81.00	82.00	72.00	68.00	66.00	68.00	60.00	57.00	54.00	54.00	47.00	47.00	43.00	49.00	39.00	41.00	33.00
Shareholder's Equity	-11.9%	122	138	92.00	124	90.00	118	123	142	161	185	188	206	221	239	179	173	185	191	195	130	144
Retained Earnings	-3.7%	-574	-554	-574	-530	-500	-470	-442	-405	-371	-340	-330	-304	-284	-261	-250	-244	-218	-203	-197	-187	-166
Additional Paid-In Capital	0.8%	700	694	659	653	587	582	550	541	534	529	521	516	511	504	431	414	401	396	390	316	312
Shares Outstanding	1.1%	64.00	64.00	60.00	60.00	48.00	48.00	45.00	45.00	45.00	45.00	44.00	44.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	260	-	-	-	243	-	-	-	459	-	-	-	285	-	-	-	511,316,440	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-152.6%	-36,741	-14,547	-24,414	-29,004	-37,400	-16,267	-20,726	-27,807	-8,298	18,828	-17,183	-21,261	9,086	-29,562	-9,141	-12,880	-12,384	-21,971	-18,405	-21,744	82,166
Share Based Compensation	0%	6,960	6,960	7,053	7,271	6,432	6,805	6,937	7,303	7,578	5,425	5,339	5,203	4,817	6,837	-	3,000	5,683	4,198	5,588	4,113	2,935
Cashflow From Investing	-46.6%	27,340	51,178	-3,564	-4,975	-8,605	-8,492	-10,011	-14,000	-12,460	-25,369	-11,905	-5,575	-18,868	-10,234	-19,834	-2,916	-4,036	-5,139	-2,023	-1,091	-1,115
Cashflow From Financing	-104.6%	-1,270	27,711	-404	57,947	-1,231	24,833	72,949	-	-2,582	1,295	54.00	223	136	69,437	13,132	-6.00	165	468	70,206	-5.47	77,566

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MGTX Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Service revenue - related party	$ 697
License revenue - related party		$ 3,334
Total revenue	697	3,334
Operating expenses:
General and administrative	13,147	12,772
Research and development	34,322	22,322
Total operating expenses	47,469	35,094
Loss from operations	(46,772)	(31,760)
Other non-operating income (expense):
Foreign currency (loss) gain	(535)	3,857
Interest income	1,097	545
Interest expense	(3,250)	(3,060)
Gain on sale of nonfinancial assets	29,018
Fair value adjustments		54
Net loss	(20,442)	(30,364)
Other comprehensive income (loss):
Foreign currency translation loss	(1,691)	(2,353)
Comprehensive loss	(22,133)	(32,717)
Net income (loss)	$ (20,442)	$ (30,364)
Basic net loss per ordinary share	$ (0.32)	$ (0.62)
Diluted net loss per ordinary share	$ (0.32)	$ (0.62)
Weighted-average number of ordinary shares outstanding, basic	64,065,895	48,638,151
Weighted-average number of ordinary shares outstanding, diluted	64,065,895	48,638,151

MGTX Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 119,206	$ 129,566
Accounts receivable - related party	10,915	10,138
Prepaid expenses	5,076	5,625
Tax incentive receivable	13,171	13,277
Other current assets	932	1,016
Total Current Assets	149,300	159,622
Property, plant and equipment, net	111,412	115,896
Intangible assets, net	1,038	1,118
Restricted cash	1,059	1,083
Other assets	1,138	1,917
Equity method and other investments	6,766	6,766
Right-of-use assets - operating leases, net	14,835	15,910
Right-of-use assets - finance leases, net	23,687	24,432
TOTAL ASSETS	309,235	326,744
CURRENT LIABILITIES:
Accounts payable	21,223	16,042
Accrued expenses	17,353	42,639
Lease obligations, current	4,188	4,193
Deferred revenue - related party, current	3,772	2,926
Other current liabilities	1,007	1,278
Total Current Liabilities	47,543	67,078
Deferred revenue - related party	53,331	34,017
Lease obligations	11,796	12,952
Asset retirement obligations	2,440	2,401
Note payable, net	72,391	72,119
TOTAL LIABILITIES	187,501	188,567
SHAREHOLDERS' EQUITY:
Ordinary Shares, $0.00003881 par value, 1,288,327,750 authorized, 64,298,691 and 63,601,015 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	2	2
Capital in excess of par value	699,531	693,841
Accumulated other comprehensive income	(3,126)	(1,435)
Accumulated deficit	(574,673)	(554,231)
Total Shareholders' Equity	121,734	138,177
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 309,235	$ 326,744

About MeiraGTx Holdings plc

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.

CEO	Dr. Alexandria Forbes Ph.D.
WEBSITE	https://meiragtx.com
INDUSTRY	Biotechnology
EMPLOYEES	406

MeiraGTx Holdings plc Frequently Asked Questions

What is the ticker symbol for MeiraGTx Holdings plc? What does MGTX stand for in stocks?

MGTX is the stock ticker symbol of MeiraGTx Holdings plc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MeiraGTx Holdings plc (MGTX)?

As of Fri May 17 2024, market cap of MeiraGTx Holdings plc is 367.19 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MGTX stock?

You can check MGTX's fair value in chart for subscribers.

What is the fair value of MGTX stock?

You can check MGTX's fair value in chart for subscribers. The fair value of MeiraGTx Holdings plc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of MeiraGTx Holdings plc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MGTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is MeiraGTx Holdings plc a good stock to buy?

The fair value guage provides a quick view whether MGTX is over valued or under valued. Whether MeiraGTx Holdings plc is cheap or expensive depends on the assumptions which impact MeiraGTx Holdings plc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MGTX.

What is MeiraGTx Holdings plc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, MGTX's PE ratio (Price to Earnings) is -4.96 and Price to Sales (PS) ratio is 26.2. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MGTX PE ratio will change depending on the future growth rate expectations of investors.